Ⅲ型前膠原氨基端原肽(PIIINP)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法)
ELISA Kit for Procollagen III N-Terminal Propeptide (PIIINP)
P3NP; N-Propeptide Of Type III Procollagen; Procollagen III Amino Terminal Propeptide
- 編號(hào)UCEA573Hu
- 物種Homo sapiens (Human，人) 相同的名稱，不同的物種。
- 實(shí)驗(yàn)方法競(jìng)爭(zhēng)抑制
- 反應(yīng)時(shí)長(zhǎng)2h
- 檢測(cè)范圍4.94-400ng/mL
- 靈敏度最小可檢測(cè)劑量小于等于2.13ng/mL.
- 樣本類型serum, plasma, tissue homogenates, cell lysates, cell culture supernates and other biological fluids
- 下載 英文說(shuō)明書 中文說(shuō)明書
- 規(guī)格 48T96T 96T*5 96T*10 96T*100
- 價(jià)格 ¥ 1323 ¥ 1890 ¥ 8505 ¥ 16065 ¥ 132300
- 欲了解實(shí)際交易價(jià)格和更多情況，請(qǐng)與當(dāng)?shù)亟?jīng)銷商聯(lián)系!
-
產(chǎn)品包裝(模擬)
-
產(chǎn)品包裝(模擬)
-
實(shí)驗(yàn)結(jié)果圖
-
標(biāo)準(zhǔn)曲線圖
-
通過(guò)ISO 9001、ISO 13485質(zhì)量體系認(rèn)證
特異性
本試劑盒用于檢測(cè)Ⅲ型前膠原氨基端原肽(PIIINP)，經(jīng)檢測(cè)與其它相似物質(zhì)無(wú)明顯交叉反應(yīng)。
由于受到技術(shù)及樣本來(lái)源的限制，不可能完成對(duì)所有相關(guān)或相似物質(zhì)交叉反應(yīng)檢測(cè)，因此本試劑盒有可能與未經(jīng)檢測(cè)的其它物質(zhì)有交叉反應(yīng)。
回收率
分別于定值血清及血漿樣本中加入一定量的Ⅲ型前膠原氨基端原肽(PIIINP)（加標(biāo)樣品），重復(fù)測(cè)定并計(jì)算其均值，回收率為測(cè)定值與理論值的比率。
| 樣本 | 回收率范圍(%) | 平均回收率(%) |
| serum(n=5) | 91-99 | 95 |
| EDTA plasma(n=5) | 95-102 | 99 |
| heparin plasma(n=5) | 84-103 | 94 |
精密度
精密度用樣品測(cè)定值的變異系數(shù)CV表示。CV(%) = SD/mean×100
批內(nèi)差：取同批次試劑盒對(duì)低、中、高值定值樣本進(jìn)行定量檢測(cè),每份樣本連續(xù)測(cè)定20 次，分別計(jì)算不同濃度樣本的平均值及SD值。
批間差：選取3個(gè)不同批次的試劑盒分別對(duì)低、中、高值定值樣本進(jìn)行定量測(cè)定，每個(gè)樣本使用同一試劑盒重復(fù)測(cè)定8次，分別計(jì)算不同濃度樣本的平均值及SD值。
批內(nèi)差： CV<10%
批間差： CV<12%
線性
在定值血清及血漿樣本內(nèi)加入適量的Ⅲ型前膠原氨基端原肽(PIIINP)，并倍比稀釋成1:2，1:4，1:8，1:16的待測(cè)樣本，線性范圍即為稀釋后樣本中Ⅲ型前膠原氨基端原肽(PIIINP)含量的測(cè)定值與理論值的比率。
| 樣本 | 1:2 | 1:4 | 1:8 | 1:16 |
| serum(n=5) | 97-105% | 78-97% | 90-104% | 93-102% |
| EDTA plasma(n=5) | 92-99% | 95-105% | 90-97% | 78-93% |
| heparin plasma(n=5) | 80-104% | 99-105% | 92-105% | 88-103% |
穩(wěn)定性
經(jīng)測(cè)定，試劑盒在有效期內(nèi)按推薦溫度保存，其活性降低率小于5%。
為減小外部因素對(duì)試劑盒破壞前后檢測(cè)值的影響，實(shí)驗(yàn)室的環(huán)境條件需盡量保持一致，尤其是實(shí)驗(yàn)室內(nèi)溫度、濕度及溫育條件。其次由同一實(shí)驗(yàn)員來(lái)進(jìn)行操作可減少人為誤差。
實(shí)驗(yàn)流程
1. 實(shí)驗(yàn)前標(biāo)準(zhǔn)品、試劑及樣本的準(zhǔn)備；
2. 加樣（標(biāo)準(zhǔn)品及樣本）50µL，
加入50µL檢測(cè)液A(臨用前配制);
37°C溫育1小時(shí)。
3. 洗板3次；
4. 加檢測(cè)溶液B100µL，37°C孵育30分鐘；
5. 洗板5次；
6. 加TMB底物90µL，37°C孵育10-20分鐘；
7. 加終止液50µL，立即450nm讀數(shù)。
實(shí)驗(yàn)原理
本試劑盒應(yīng)用競(jìng)爭(zhēng)抑制酶聯(lián)免疫分析法測(cè)定標(biāo)本中待測(cè)物質(zhì)水平。將Ⅲ型前膠原氨基端原肽(PIIINP)單克隆抗體包被微孔板，制成固相載體，往包被抗體的微孔中同時(shí)加入生物素標(biāo)記的抗原和待測(cè)抗原(標(biāo)準(zhǔn)品或樣本)，待測(cè)抗原與生物素標(biāo)記抗原對(duì)特異性抗體進(jìn)行競(jìng)爭(zhēng)結(jié)合。溫育后經(jīng)洗滌去掉未結(jié)合物，然后加入HRP標(biāo)記的親和素，經(jīng)過(guò)溫育和徹底洗滌后加入底物TMB顯色。TMB在過(guò)氧化物酶的催化下轉(zhuǎn)化成藍(lán)色，并在酸的作用下轉(zhuǎn)化成最終的黃色。待測(cè)標(biāo)本濃度越高，標(biāo)記抗原和抗體的結(jié)合就越受到抑制，顯色愈淺。顯色的深淺與酶量呈正相關(guān)，而與樣品中待測(cè)物質(zhì)含量呈負(fù)相關(guān)。用酶標(biāo)儀在450nm波長(zhǎng)下測(cè)定吸光度（O.D.值），計(jì)算樣品濃度。
贈(zèng)品
相關(guān)產(chǎn)品
| 編號(hào) | 適用物種：Homo sapiens (Human，人) | 應(yīng)用(僅供研究使用，不用于臨床診斷！) |
| URPA573Hu02 | Ⅲ型前膠原氨基端原肽(PIIINP)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| UEPA573Hu62 | Ⅲ型前膠原氨基端原肽(PIIINP)真核蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| UEPA573Hu63 | Ⅲ型前膠原氨基端原肽(PIIINP)真核蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| URPA573Hu01 | Ⅲ型前膠原氨基端原肽(PIIINP)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| UAPA573Hu61 | Ⅲ型前膠原氨基端原肽(PIIINP)活性蛋白 | Cell?culture;?Activity?Assays. |
| UEPA573Hu61 | Ⅲ型前膠原氨基端原肽(PIIINP)真核蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| UCPA573Hu21 | Ⅲ型前膠原氨基端原肽(PIIINP)卵白蛋白偶聯(lián)物 | Immunogen; SDS-PAGE; WB. |
| USPA573Hu02 | Ⅲ型前膠原氨基端原肽(PIIINP)合成多肽 | Immunogen; Blocking Peptide. |
| UCPA573Hu22 | Ⅲ型前膠原氨基端原肽(PIIINP)卵白蛋白偶聯(lián)物 | Immunogen; SDS-PAGE; WB. |
| UCPA573Hu31 | Ⅲ型前膠原氨基端原肽(PIIINP)鑰孔血藍(lán)蛋白偶聯(lián)物 | Immunogen; SDS-PAGE; WB. |
| USPA573Hu01 | Ⅲ型前膠原氨基端原肽(PIIINP)合成多肽 | Immunogen; Blocking Peptide. |
| USPA573Hu71 | Ⅲ型前膠原氨基端原肽(PIIINP)合成多肽 | Immunogen; Blocking Peptide. |
| UPAA573Hu01 | Ⅲ型前膠原氨基端原肽(PIIINP)多克隆抗體 | WB; IHC |
| UPAA573Hu02 | Ⅲ型前膠原氨基端原肽(PIIINP)多克隆抗體 | WB; IHC; ICC/IF |
| UPAA573Hu09 | Ⅲ型前膠原氨基端原肽(PIIINP)多克隆抗體 | WB; IHC; ICC; IP. |
| UPAA573Hu08 | Ⅲ型前膠原氨基端原肽(PIIINP)多克隆抗體 | WB; IHC; ICC; IP. |
| ULAA573Hu71 | Ⅲ型前膠原氨基端原肽(PIIINP)多克隆抗體(生物素標(biāo)記) | WB; IHC; ICC. |
| UMAA573Hu23 | Ⅲ型前膠原氨基端原肽(PIIINP)單克隆抗體 | WB; IHC |
| UMAA573Hu24 | Ⅲ型前膠原氨基端原肽(PIIINP)單克隆抗體 | WB; IHC |
| UMAA573Hu27 | Ⅲ型前膠原氨基端原肽(PIIINP)單克隆抗體 | WB; IHC; ICC/IF |
| UMAA573Hu28 | Ⅲ型前膠原氨基端原肽(PIIINP)單克隆抗體 | WB |
| UMAA573Hu26 | Ⅲ型前膠原氨基端原肽(PIIINP)單克隆抗體 | IHC; FCM |
| UMAA573Hu29 | Ⅲ型前膠原氨基端原肽(PIIINP)單克隆抗體 | WB |
| UMAA573Hu25 | Ⅲ型前膠原氨基端原肽(PIIINP)單克隆抗體 | WB |
| UMAA573Hu21 | Ⅲ型前膠原氨基端原肽(PIIINP)單克隆抗體 | WB; IHC |
| UMAA573Hu22 | Ⅲ型前膠原氨基端原肽(PIIINP)單克隆抗體 | WB; IHC |
| UFAA573Hu04 | 抗Ⅲ型前膠原氨基端原肽(PIIINP)單克隆抗體 | FCM |
| UFAA573Hu08 | 抗Ⅲ型前膠原氨基端原肽(PIIINP)單克隆抗體 | FCM |
| UFAA573Hu06 | 抗Ⅲ型前膠原氨基端原肽(PIIINP)單克隆抗體 | FCM |
| UFAA573Hu02 | 抗Ⅲ型前膠原氨基端原肽(PIIINP)單克隆抗體 | FCM |
| ULAA573Hu94 | Ⅲ型前膠原氨基端原肽(PIIINP)單克隆抗體(辣根過(guò)氧化物酶標(biāo)記) | IHC; ICC |
| UHEA573Hu | Ⅲ型前膠原氨基端原肽(PIIINP)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法,高敏型) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| USEA573Hu | Ⅲ型前膠原氨基端原肽(PIIINP)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| UCEA573Hu | Ⅲ型前膠原氨基端原肽(PIIINP)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| ULMA573Hu | Ⅲ型前膠原氨基端原肽(PIIINP)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
| UPSA573Hu01 | Ⅲ型前膠原氨基端原肽(PIIINP)抗體對(duì) | ELISA; CLIA; ELISPOT; Luminex; Immunochromatography and other Immunoassays. |
| UKSA573Hu11 | Ⅲ型前膠原氨基端原肽(PIIINP)檢測(cè)試劑盒DIY材料(酶聯(lián)免疫吸附試驗(yàn)法) | Main materials for "Do It (ELISA Kit) Yourself". |
| UKSA573Hu01 | Ⅲ型前膠原氨基端原肽(PIIINP)檢測(cè)試劑盒DIY材料(酶聯(lián)免疫吸附試驗(yàn)法) | 自己動(dòng)手制作ELISA試劑盒的主要材料 |
參考文獻(xiàn)
| 雜志 | 參考文獻(xiàn) |
| Molecular Biology Reports | Characterization of the specific and sustained GH1 expression induced by rAAV2/1 in normal adult male rats [PubMed: 20204528] |
| Obesity Surgery | A Biomarker Panel for Non-alcoholic Steatohepatitis (NASH) and NASH-Related Fibrosis [PubMed: 20532833] |
| Liver Biopsy | Comparison of Five Liver Fibrosis Indexes with Serum Levels of Laminin and N Terminal Peptide of Procollagen Type III in Chronic Hepatitis Patients [Intechopen: 18785] |
| Trials | Is there benefit in optimising heart failure treatment in over-80 year-old patients? (HF-80 study): study protocol for a randomized controlled trial. [Trials: 1745-6215] |
| American Journal of Hypertension | Aliskiren and Perindopril Reduce the Levels of Transforming Growth Factor-β in Patients With Non-Diabetic Kidney Disease [Nature: 201214] |
| Arthritis Research and Therapy | Raised circulating tenascin-C in rheumatoid arthritis. [PubMed: 23193984] |
| American Heart Journal | Serum markers of deranged myocardial collagen turnover: their relation to malignant ventricular arrhythmias in cardioverter-defibrillator recipients with heart failure. [PubMed: 23067911] |
| hepatology research | Diagnostic potential of serum direct markers and non-invasive fibrosis models in patients with chronic hepatitis B. [PubMed: 22734888] |
| Digestive and Liver Disease | Effects of coffee consumption in chronic hepatitis C: a randomized controlled trial [Pubmed: 23238034] |
| Journal of Infectious Diseases | Procollagen III N-terminal propeptide and desmosine are released by matrix destruction in pulmonary tuberculosis [Pubmed: 23922364] |
| International Urogynecology Journal | Prevalence, etiology and risk factors of pelvic organ prolapse in premenopausal primiparous women [Springer: Source] |
| Journal of Clinical and Experimental Hepatology | Protective Effects of Norursodeoxycholic Acid Versus Ursodeoxycholic Acid on Thioacetamide-induced Rat Liver Fibrosis [ScienceDirect: S0973688314000073] |
| Der Urologe | Retroperitoneale Fibrose [Springer:Source] |
| Ultrasound in Obstetrics & Gynecology | The status of the pelvic floor in young primiparous women [Wiley:Source] |
| PLoS One. | Clinical significance of markers of collagen metabolism in rheumatic mitral valve disease [Pubmed:24603967] |
| Clin Chim Acta. | Serum and urinary procollagen III aminoterminal propeptide as a biomarker of obstructive nephropathy in children [Pubmed:24768785] |
| BMC Gastroenterol. | Fast food diet with CCl4 micro-dose induced hepatic-fibrosis-a novel animal model [Pubmed:24884574] |
| Toxicology. | DNMT3A silencing RASSF1A promotes cardiac fibrosis through upregulation of ERK1/2 [Pubmed:24945829] |
| Southeast Asian J Trop Med Public Health. | Correlation of HBsAg titers with serum fibrotic maker in patients with chronic hepatitis B infection. [Pubmed:24974647] |
| The American Journal of Cardiology | Relation of burden of myocardial fibrosis to malignant ventricular arrhythmias and outcomes in Fabry disease [Pubmed:25073565] |
| Ann Rheum Dis. | B-cell depletion attenuates serological biomarkers of fibrosis and myofibroblast activation in IgG4-related disease [Pubmed:25143523] |
| Scientific Reports | Biomarkers and Echocardiographic Predictors of Myocardial Dysfunction in Patients with Hypertension [PubMed: 25747153] |
| Int J Mol Sci | The Multi-Biomarker Approach for Heart Failure in Patients with Hypertension [PubMed: 25984599] |
| Viral Hepatitis Journal | The Relationship of the Degree of Hepatic Fibrosis with Hyaluronic Acid, Type 4 Collagen, and Procollagen Type 3 N-Terminal Peptide Levels in Patients with Chronic Viral Hepatitis [Openview: 8A0B8C97D72C61741371F33508760B75] |
| International Journal of Experimental Pathology | Pathological characterization and morphometric analysis of hepatic lesions in SHRSP5/Dmcr, an experimental non-alcoholic steatohepatitis model, induced by high-fat and high-cholesterol diet [doi:10.1111] |
| Heart Rhythm.? | Prognostic value of collagen turnover biomarkers in cardiac resynchronization therapy: A subanalysis of the TRUST CRT randomized trial population [Pubmed:26776557] |
| BMJ Open Sport Exerc Med | Procollagen markers in microdialysate can predict patient outcome after Achilles tendon rupture [content:2] |
| Inflammation Research | Fibrosis of extracellular matrix is related to the duration of the disease but is unrelated to the dynamics of collagen metabolism in dilated cardiomyopathy [pubmed:27516211] |
| Heart & Vessels | Left ventricular reverse remodeling is not related to biopsy-detected extracellular matrix fibrosis and serum markers of fibrosis in dilated cardiomyopathy, regardless of the definition used for LVRR [pubmed:28004175] |
| american journal of physiology-renal physiology | Extracellular microRNA signature in chronic kidney disease. [pubmed:28077372] |
| Cellular?Physiology and Biochemistry | Renal Denervation Attenuates Multi-Organ Fibrosis and Improves Vascular Remodeling in Rats with Transverse Aortic Constriction Induced Cardiomyopathy [pubmed:27889753] |
| PLoS One. | Procollagen?C-Proteinase?Enhancer?1?(PCPE-1) as a?Plasma?Marker?of?Muscleand?Liver Fibrosis?in?Mice. [pubmed:27458976] |
| International?Journal?of?Cardiology | 5-methoxytryptophan?is a?potential?marker?for?post-myocardial?infarction?heart?failure - apreliminary?approach?to?clinical?utility. [pubmed:27526355] |
| Transplant Proc | Urinary Type III Procollagen Is Associated With Chronic Allograft Dysfunction and Predicts Graft Survival. [pubmed:28219585] |
| Knee Surg Sports Traumatol Arthrosc | Achilles tendon rupture healing is enhanced by intermittent pneumatic compression upregulating collagen type I synthesis [pubmed:28668970] |
| Antiviral Therapy | Association of HIV infection with biomarkers of kidney injury and fibrosis in the Multicenter AIDS Cohort Study [pubmed:28054933] |
| Molecular?Medicine?Reports | Profilin?1 contributes to cardiac injury induced by advanced glycation end?products in rats [pubmed:28901418] |
| Biomarkers Medicial | Relationship of biomarkers of extracellular matrix with myocardial function in Type 2 diabetes mellitus [pubmed:28685602] |
| Heart and Vessels | Left ventricular reverse remodeling is not related to biopsy?detected extracellular matrix fibrosis and serum markers of fibrosis in dilated cardiomyopathy, regardless of the definition used for LVRR [10.1007/s00380-016-0930-y] |
| Clinical Infectious Diseases | Matrix Degradation in Human Immunodeficiency Virus Type 1–Associated Tuberculosis and Tuberculosis Immune Reconstitution Inflammatory Syndrome: A Prospective Observational Study [10.1093/cid/cix231] |
| Cytokine | 12-month patterns of serum markers of collagen synthesis, transforming growth factor and connective tissue growth factor are similar in new-onset and chronic dilated cardiomyopathy in patients both with and without cardiac fibrosis. [pubmed:28460256] |
| Advanced Healthcare Materials | Prognostic value of fibrosis-related markers in dilated cardiomyopathy: A link between osteopontin and cardiovascular events. [pubmed:29120858] |
| American Journal of?Kidney?Diseases | Urinary Biomarkers of Kidney Tubular Damage and Risk of Cardiovascular Disease and Mortality in Elders [Pubmed:29602632] |
| Angiology | The Association of Biomarkers of Inflammation and Extracellular Matrix Degradation With the Risk of Abdominal Aortic Aneurysm: The ARIC Study [article:10.1007] |
| Hernia | Circulating matrix metalloproteinases and procollagen propeptides in inguinal hernia [Pubmed:29484522] |
| Cardiovascular Journal of Africa | Assessment of myocardial fibrosis by late gadolinium enhancement imaging and biomarkers of collagen metabolism in chronic rheumatic mitral regurgitation. [Pubmed:29443354] |
| Turk Kardiyol Dern Ars.? | Association between reverse electrical remodeling and cardiac fibrosis markers in patients with cardiac resynchronization therapy [Pubmed:29512624] |
| Кардиоваскулярная терапия и профилактика | N-терминальный пропептид проколлагена III типа в качестве возможного сывороточного маркера фиброза миокарда у больных сахарным диабетом 2?… [:] |
| Clinical?Infectious?Diseases | Improvement in Hepatic Fibrosis Biomarkers Associated with Chemokine Receptor Inactivation through Mutation or Therapeutic Blockade [Pubmed: 30239650] |
| Anatolian Journal of Cardiology | microRNA-29a inhibits cardiac fibrosis in Sprague-Dawley rats by downregulating the expression of DNMT3A. [Pubmed: 30297596] |
| Contemporary?Clinical?Trials | Methods to improve the noninvasive diagnosis and assessment of disease severity in children with suspected nonalcoholic fatty liver disease (NAFLD): Study design [Doi: 10.1016/j.cct.2018.10.012] |
| Arthritis?Research &?Therapy | Association of serum levels of fibrosis-related biomarkers with disease activity in patients with IgG4-related disease [Pubmed: 30547825] |
| American Journal of Respiratory and?Critical?Care?Medicine | Identification and Modulation of Microenvironment is Crucial for Effective MSC Therapy in Acute Lung Injury [Pubmed: 30521764] |
| Direktor: Prof. Dr. med. Andreas Mügge [] | |
| Scientific Reports | Low fibrosis biomarker levels predict cardiac resynchronization therapy response [Pubmed: 30988339] |
| American Journal of Translational Research | Development and validation of an in vitro 3D model of NASH with severe fibrotic phenotype [Pubmed: 30972180] |
| Food and Chemical Toxicology | Gum Acacia mitigates diclofenac nephrotoxicity by targeting monocyte chemoattractant protein-1, complement receptor-1 and pro-apoptotic pathways [Pubmed: 31042592] |
| Digestive diseases and sciences | Validation and Refinement of Noninvasive Methods to Assess Hepatic Fibrosis: Magnetic Resonance Elastography Versus Enhanced Liver Fibrosis Index [Pubmed: 31468264] |
| Journal of Diabetes Research | Type 2 Diabetes Mellitus and Chronic Heart Failure with Midrange and Preserved Ejection Fraction: A Focus on Serum Biomarkers of Fibrosis [Pubmed: 33224989] |
| BMC GASTROENTEROLOGY | Changes in hepatic fibrosis and vitamin D levels after viral hepatitis C eradication using direct-acting antiviral therapy [Pubmed: 33069226] |
| european heart journal | A randomized controlled trial of dapagliflozin on left ventricular hypertrophy in people with type two diabetes: the DAPA-LVH trial [Pubmed: 32578850] |
| Ассоциации толщины эпикардиального жира и циркулирующих маркеров фиброза миокарда у пациентов с инфарктом миокарда [] | |
| J Am Geriatr Soc | Association of Non?\Steroidal Anti?\Inflammatory Drugs with Kidney Health in Ambulatory Older Adults [33305369] |
| Aging (Albany NY) | Prognostic potential of cardiac structural and functional parameters and N-terminal propeptide of type III procollagen in predicting cardiac fibrosis one year after??- [33431713] |
| PeerJ | Effect of vitamin D supplementation in patients with chronic hepatitis C after direct-acting antiviral treatment: a randomized, double-blind, placebo-controlled trial [33614272] |
| Open Forum Infectious Diseases | Soluble CD163 Identifies Those at Risk for Increased Hepatic Inflammation & Fibrosis [34104667] |
| European Heart Journal | A randomized controlled trial of dapagliflozin on left ventricular hypertrophy in people with type two diabetes [32578850] |
| Nutrients | The Effect of Daily Methylsulfonylmethane (MSM) Consumption on High-Density Lipoprotein Cholesterol in Healthy Overweight and Obese Adults: A Randomized?… [34684621] |
| J Diabetes Res | Association between Markers of Fibrosis and Heart Failure Incidence in Patients with Type 2 Diabetes Mellitus [34778465] |
| Scandinavian Cardiovascular Journal | Dual integrin αvβ3 and αvβ5 blockade attenuates cardiac dysfunction by reducing fibrosis in a rat model of doxorubicin-induced cardiomyopathy [34296634] |
| J. Clin. Med | Simple Predictors for Cardiac Fibrosis in Patients with Type 2 Diabetes Mellitus: The Role of Circulating Biomarkers and Pulse Wave Velocity [Pubmed:35628969] |
| Biomolecules | Increase in Serum MMP-9 and TIMP-1 Concentrations during Alcohol Intoxication in Adolescents—A Preliminary Study [Pubmed:35625637] |
留言咨詢
